If the news has not broken before market open tomorrow, I think I'll buy a (small for now) ARTH slice. Going over some material, it looks like they have something and the upcoming FDA decision may give it more of a push, ... if positive :) Not sure about how close the decision may be given the 510k process, but you guys on that MB are doing some nice DD. So starting small at the open.
FYI, my best pick this year is CYRX in the biotech, it had a big pull back recently, but still really up since I bought it in May. (My worse one on paper so far is NWBO, but that game ain't over yet. I think there is a strong possibility for a big up. :)
My other best pick in the non-biotech is YRD.
I'm not saying Buy; I just like those two (and NWBO) and I hope to keep them for 'a while' :)) Just in case you might be interested.
Cheers!
Recent AGEN News
- Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement • Business Wire • 05/01/2024 11:30:00 AM
- Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting • Business Wire • 04/24/2024 02:00:00 PM
- Agenus to Provide First Quarter 2024 Financial Report and Corporate Update • Business Wire • 04/23/2024 11:30:00 AM
- Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer • Business Wire • 04/12/2024 11:30:00 AM
- Agenus Announces Reverse Stock Split of Common Stock • Business Wire • 04/05/2024 08:30:00 PM
- Agenus Reports Fourth Quarter and Full Year 2023 Results • Business Wire • 03/14/2024 11:30:00 AM
- Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024 • Business Wire • 03/06/2024 12:30:00 PM
- Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/05/2024 09:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/29/2024 09:50:48 PM
- Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report • Business Wire • 02/29/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/26/2024 09:24:59 PM
- Agenus to Participate in Leerink Partners Global Biopharma Conference • Business Wire • 02/26/2024 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/15/2024 01:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 01:00:11 PM
- Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design • PR Newswire (US) • 02/15/2024 12:02:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:33:12 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 12:00:12 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 10:11:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 01:00:10 PM
- Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference • Business Wire • 01/31/2024 12:30:00 PM
- Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population • Business Wire • 01/22/2024 02:59:00 PM
- Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population • Business Wire • 01/22/2024 12:30:00 PM
- Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/05/2024 09:30:00 PM
- Agenus to Participate in B. Riley Healthcare Conference • Business Wire • 01/04/2024 12:30:00 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM